Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients? — Ying X. Gue (2022) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?
Shared by
Professor Gregory Lip
University of Liverpool
Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?
Letter
2022
en
Authors
YG
Ying X. Gue
DG
Diana A. Gorog
Professor Gregory Lip
University of Liverpool
Abstract
1 min read
© 2022 American Heart Association, Inc. This is the accepted manuscript version of an Editorial which has been published in final form at https://doi.org/10.1161/CIRCULATIONAHA.122.061987
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Letter
2022
Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease
Ying X. Gue
,
Diana A. Gorog
,
Professor Gregory Lip
Article
2021
Rural schools as effective hubs for agricultural technology dissemination: experimental evidence from Tanzania and Uganda
Henry Musa Kpaka
,
Tesfamicheal Wossen
,
Dan Joseph Stein
,
Kiddo Mtunda
,
Lembris Laizer
,
Shiferaw Feleke
,
Victor M. Manyong
Article
2009
Response to “Unsupported Claims of Ultrafast Charging of Li-ion Batteries”
Gerbrand Ceder
,
Byoungwoo Kang
Editorial Material
2023
Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Liver Disease
Theresa Hydes
,
Professor Gregory Lip
,
Deirdre A. Lane
Letter
2022
Atrial Cardiopathy and Cardioembolic Stroke
Darae Ko
,
Emelia Benjamin
Discussion(0)
No comments yet. Be the first to comment.